Charles J Sherr

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5036870/publications.pdf

Version: 2024-02-01

		10351	5806
173 papers	44,354 citations	72 h-index	161 g-index
175 all docs	175 docs citations	175 times ranked	29559 citing authors

#	ARTICLE	IF	CITATIONS
1	Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell, 2020, 181, 424-441.e21.	13.5	216
2	Surprising regulation of cell cycle entry. Science, 2019, 366, 1315-1316.	6.0	8
3	Sexually dimorphic tumor suppression by small mitochondrial Arf. Oncotarget, 2019, 10, 1235-1237.	0.8	0
4	The D-Type Cyclins: A Historical Perspective. Current Cancer Research, 2018, , 1-26.	0.2	5
5	NK cellâ€“mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science, 2018, 362, 1416-1422.	6.0	267
6	Acquired palbociclib resistance in KRAS-mutant lung cancer. Oncotarget, 2018, 9, 32734-32735.	0.8	3
7	Mouse medulloblastoma driven by CRISPR activation of cellular Myc. Scientific Reports, 2018, 8, 8733.	1.6	17
8	Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. Cell Reports, 2017, 18, 2907-2917.	2.9	61
9	Small mitochondrial Arf (smArf) protein corrects p53-independent developmental defects of <i>Arf</i> tumor suppressor-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7420-7425.	3.3	9
10	Cell Cycleâ€“Targeted Cancer Therapies. Annual Review of Cancer Biology, 2017, 1, 41-57.	2.3	88
11	A New Cell-Cycle Target in Cancer â€” Inhibiting Cyclin Dâ€“Dependent Kinases 4 and 6. New England Journal of Medicine, 2016, 375, 1920-1923.	13.9	36
12	Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discovery, 2016, 6, 353-367.	7.7	717
13	Abstract IA21: Mitogenic signaling and the RB/p53 network. , 2016, , .		0
14	Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. Blood, 2015, 125, 1444-1451.	0.6	35
15	Forging a signature of in vivo senescence. Nature Reviews Cancer, 2015, 15, 397-408.	12.8	775
16	Simultaneous Gene Editing by Injection of mRNAs Encoding Transcription Activator-Like Effector Nucleases into Mouse Zygotes. Molecular and Cellular Biology, 2014, 34, 1649-1658.	1.1	26
17	Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. Pharmacogenetics and Genomics, 2014, 24, 263-271.	0.7	9
18	CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes and Development, 2014, 28, 1800-1814.	2.7	167

#	ARTICLE	IF	CITATIONS
19	Epigenetic regulation of the Ink4a-Arf (Cdkn2a) tumor suppressor locus in the initiation and progression of Notch1-driven T cell acute lymphoblastic leukemia. Experimental Hematology, 2013, 41, 377-386.	0.2	12
20	<i>Arf</i> tumor suppressor and miR-205 regulate cell adhesion and formation of extraembryonic endoderm from pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1112-21.	3.3	27
21	Prevention Of Minimal Residual Disease In Ph+ ALL. Blood, 2013, 122, 1265-1265.	0.6	0
22	<i>Ink4â€Arf</i> locus in cancer and aging. Wiley Interdisciplinary Reviews: Developmental Biology, 2012, 1, 731-741.	5.9	85
23	How politics trumped peer review at Texas cancer institute. BMJ, The, 2012, 345, e7334-e7334.	3.0	0
24	Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness. Blood, 2012, 120, 3560-3560.	0.6	0
25	Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosomeâ€"positive acute lymphoblastic leukemia. Blood, 2011, 117, 3585-3595.	0.6	73
26	Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies. Blood, 2011, 117, 5453-5462.	0.6	30
27	Expression of Arf Tumor Suppressor in Spermatogonia Facilitates Meiotic Progression in Male Germ Cells. PLoS Genetics, 2011, 7, e1002157.	1.5	27
28	Developmental strategies for evasion ofArftumor suppression. Cell Cycle, 2010, 9, 14-15.	1.3	8
29	Atoh1 Inhibits Neuronal Differentiation and Collaborates with Gli1 to Generate Medulloblastoma-Initiating Cells. Cancer Research, 2010, 70, 5618-5627.	0.4	87
30	Transient expression of the <i>Arf</i> tumor suppressor during male germ cell and eye development in <i>Arf-Cre</i> reporter mice. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6285-6290.	3.3	40
31	Two Tumor Suppressors, p27Kip1 and Patched-1, Collaborate to Prevent Medulloblastoma. Molecular Cancer Research, 2009, 7, 33-40.	1.5	55
32	Rescue of key features of the p63-null epithelial phenotype by inactivation of Ink4a and Arf. EMBO Journal, 2009, 28, 1904-1915.	3.5	66
33	Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia. Blood, 2009, 114, 4451-4459.	0.6	23
34	Developmentally Restricted Protection From Notch1-Induced T Cell Acute Lymphoblastic Leukemia by the Arf Tumor Suppressor.. Blood, 2009, 114, 143-143.	0.6	13
35	Abstract A253: Acquired Bcrâ€Abl kinase domain mutations are not responsible for persistence of dasatinibâ€refractory disease in murine Ph+ALL. , 2009, , .		0
36	Hzf regulates adipogenesis through translational control of C/EBPÎ±. EMBO Journal, 2008, 27, 1481-90.	3.5	22

#	ARTICLE	IF	CITATIONS
37	BCRâ€"ABL and CDKN2A: a dropped connection. Nature Reviews Cancer, 2008, 8, 563-563.	12.8	9
38	Differential post-transcriptional regulation of two Ink4 proteins, p18Ink4c and p19Ink4d. Cell Cycle, 2008, 7, 3737-3746.	1.3	16
39	Failure of <i>CDKN2A/B</i> (<i>INK4A/Bâ€"ARF</i>)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes and Development, 2008, 22, 1411-1415.	2.7	84
40	Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3. Cell Cycle, 2008, 7, 3378-3387.	1.3	64
41	Genetic Alterations in Mouse Medulloblastomas and Generation of Tumors De novo from Primary Cerebellar Granule Neuron Precursors. Cancer Research, 2007, 67, 2676-2684.	0.4	66
42	Cytokine-dependent imatinib resistance in mouse BCR-ABL⁺, <i>Arf</i>-null lymphoblastic leukemia. Genes and Development, 2007, 21, 2283-2287.	2.7	166
43	Regulation of the Arf tumor suppressor in EÎ¼-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis. Blood, 2007, 109, 792-794.	0.6	17
44	The Arf Tumor Suppressor in Acute Leukemias: Insights from Mouse Models of Bcrâ€"Abl-Induced Acute Lymphoblastic Leukemia. Advances in Experimental Medicine and Biology, 2007, 604, 107-114.	0.8	13
45	Autophagy by ARF: A Short Story. Molecular Cell, 2006, 22, 436-437.	4.5	20
46	Divorcing ARF and p53: an unsettled case. Nature Reviews Cancer, 2006, 6, 663-673.	12.8	535
47	The CDK Inhibitor p18Ink4c is a Tumor Suppressor in Medulloblastoma. Cell Cycle, 2006, 5, 363-365.	1.3	32
48	Hzf , a p53-Responsive Gene, Regulates Maintenance of the G 2 Phase Checkpoint Induced by DNA Damage. Molecular and Cellular Biology, 2006, 26, 502-512.	1.1	30
49	Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6688-6693.	3.3	182
50	N-Myc and the cyclin-dependent kinase inhibitors p18Ink4c and p27Kip1 coordinately regulate cerebellar development. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11579-11583.	3.3	69
51	Inactivation of the Arf Tumor Suppressor in Mouse BCR-ABL(+) B Cells Greatly Increases the Frequency of Leukemia-Initiating Cells and Confers Imatinib Resistance In Vivo.. Blood, 2006, 108, 385-385.	0.6	1
52	The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes and Development, 2005, 19, 2656-2667.	2.7	133
53	Tbx3, the ulnar-mammary syndrome gene, andTbx2interact in mammary gland development through a p19Arf/p53-independent pathway. Developmental Dynamics, 2005, 234, 922-933.	0.8	72
54	Ras-Raf-Arf Signaling Critically Depends on the Dmp1 Transcription Factor. Molecular and Cellular Biology, 2005, 25, 220-232.	1.1	109

#	ARTICLE	IF	CITATIONS
55	Myeloid Leukemia-Associated Nucleophosmin Mutants Perturb p53-Dependent and Independent Activities of the Arf Tumor Suppressor Protein. Cell Cycle, 2005, 4, 1593-1598.	1.3	95
56	Sumoylation induced by the Arf tumor suppressor: A p53-independent function. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7689-7694.	3.3	107
57	Living with or without cyclins and cyclin-dependent kinases. Genes and Development, 2004, 18, 2699-2711.	2.7	945
58	Erk2 Signaling and Early Embryo Stem Cell Self-Renewal. Cell Cycle, 2004, 3, 239-241.	1.3	29
59	N-Terminal Polyubiquitination of the ARF Tumor Suppressor, A Natural Lysine-Less Protein. Cell Cycle, 2004, 3, 1367-1369.	1.3	18
60	AnArfGFP/GFPIndicator Mouse Reveals that theArfTumor Suppressor Monitors Latent Oncogenic Signals In Vivo. Cell Cycle, 2004, 3, 237-238.	1.3	4
61	Physical and Functional Interactions of the Arf Tumor Suppressor Protein with Nucleophosmin/B23. Molecular and Cellular Biology, 2004, 24, 985-996.	1.1	351
62	Antagonism of Myc functions by Arf. Cancer Cell, 2004, 6, 309-311.	7.7	36
63	Monoclonal Antibodies to the Mouse p19ArfTumor Suppressor Protein. Hybridoma, 2004, 23, 293-300.	0.6	26
64	N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes and Development, 2004, 18, 1862-1874.	2.7	180
65	Principles of Tumor Suppression. Cell, 2004, 116, 235-246.	13.5	850
66	Expression arrays illuminate a way forward for mantle cell lymphoma. Cancer Cell, 2003, 3, 100-102.	7.7	4
67	Bared essentials of CDK2 and cyclin E. Nature Genetics, 2003, 35, 8-9.	9.4	27
68	Tumor suppression by Ink4aâ€"Arf: progress and puzzles. Current Opinion in Genetics and Development, 2003, 13, 77-83.	1.5	666
69	Nucleolar Arf Tumor Suppressor Inhibits Ribosomal RNA Processing. Molecular Cell, 2003, 11, 415-424.	4.5	267
70	Myc-Mediated Proliferation and Lymphomagenesis, but Not Apoptosis, Are Compromised by E2f1 Loss. Molecular Cell, 2003, 11, 905-914.	4.5	91
71	Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15930-15935.	3.3	139
72	Oncogenic Potential of the c-FMS Proto-Oncogene (CSF-1 Receptor). Cell Cycle, 2003, 2, 5-6.	1.3	14

#	ARTICLE	IF	CITATIONS
73	Arf induces p53-dependent and -independent antiproliferative genes. Cancer Research, 2003, 63, 1046-53.	0.4	92
74	Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice. Cancer Research, 2003, 63, 5420-7.	0.4	55
75	D1 in G2. Cell Cycle, 2002, 1, 32-34.	1.3	23
76	The RB and p53 pathways in cancer. Cancer Cell, 2002, 2, 103-112.	7.7	1,473
77	The RING domain of Mdm2 can inhibit cell proliferation. Cancer Research, 2002, 62, 1222-30.	0.4	59
78	Parsing Ink4a/Arf. Cell, 2001, 106, 531-534.	13.5	69
79	The INK4a/ARF network in tumour suppression. Nature Reviews Molecular Cell Biology, 2001, 2, 731-737.	16.1	890
80	Control of Spermatogenesis in Mice by the Cyclin D-Dependent Kinase Inhibitors p18 Ink4c and p19 Ink4d. Molecular and Cellular Biology, 2001, 21, 3244-3255.	1.1	103
81	Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes and Development, 2001, 15, 2934-2939.	2.7	101
82	p53-independent functions of the p19ARF tumor suppressor. Genes and Development, 2000, 14, 2358-2365.	2.7	317
83	<i>INK4d</i>-Deficient Mice Are Fertile Despite Testicular Atrophy. Molecular and Cellular Biology, 2000, 20, 372-378.	1.1	129
84	Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex. Molecular and Cellular Biology, 2000, 20, 2517-2528.	1.1	260
85	The ARF/p53 pathway. Current Opinion in Genetics and Development, 2000, 10, 94-99.	1.5	612
86	Cellular Senescence. Cell, 2000, 102, 407-410.	13.5	720
87	Oncogenic Ras Induces p19ARF and Growth Arrest in Mouse Embryo Fibroblasts Lacking p21Cip1 and p27Kip1 without Activating Cyclin D-dependent Kinases. Journal of Biological Chemistry, 2000, 275, 27473-27480.	1.6	60
88	Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes and Development, 2000, 14, 1797-1809.	2.7	89
89	Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biology, 1999, 1, 20-26.	4.6	854
90	A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. Oncogene, 1999, 18, 573-582.	2.6	94

#	ARTICLE	IF	CITATIONS
91	p27KIP1 Deletions in Childhood Acute Lymphoblastic Leukemia. Neoplasia, 1999, 1, 253-261.	2.3	37
92	Cloning and chromosomal localization of the gene encoding human cyclin D-binding Myb-like protein (hDMP1). Gene, 1999, 229, 223-228.	1.0	36
93	Cyclin D- and E-Dependent Kinases and the p57^{<i>KIP2</i>} Inhibitor: Cooperative Interactions In Vivo. Molecular and Cellular Biology, 1999, 19, 353-363.	1.1	63
94	CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and Development, 1999, 13, 1501-1512.	2.7	5,227
95	Tumor surveillance via the ARFâ€“p53 pathway. Genes and Development, 1998, 12, 2984-2991.	2.7	641
96	Regulation of the CD13/Aminopeptidase N Gene by DMP1, a Transcription Factor Antagonized by D-Type Cyclins. Journal of Biological Chemistry, 1998, 273, 29188-29194.	1.6	40
97	Gene Expression and Cell Cycle Arrest Mediated by Transcription Factor DMP1 Is Antagonized by D-Type Cyclins through a Cyclin-Dependent-Kinase-Independent Mechanism. Molecular and Cellular Biology, 1998, 18, 1590-1600.	1.1	158
98	Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF. Cell, 1997, 91, 649-659.	13.5	1,519
99	Features of Macrophage Differentiation Induced by p19INK4d, a Specific Inhibitor of Cyclin Dâ€“Dependent Kinases. Blood, 1997, 90, 126-137.	0.6	48
100	Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene, 1997, 15, 203-211.	2.6	527
101	Features of Macrophage Differentiation Induced by p19INK4d, a Specific Inhibitor of Cyclin Dâ€“Dependent Kinases. Blood, 1997, 90, 126-137.	0.6	19
102	Cancer Cell Cycles. Science, 1996, 274, 1672-1677.	6.0	4,932
103	D-type cyclins. Trends in Biochemical Sciences, 1995, 20, 187-190.	3.7	905
104	Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 1995, 83, 993-1000.	13.5	1,393
105	Molecular Cloning, Expression Pattern, and Chromosomal Localization of Human CDKN2D/INK4d,an Inhibitor of Cyclin D-Dependent Kinases. Genomics, 1995, 29, 623-630.	1.3	58
106	The ins and outs of RB: coupling gene expression to the cell cycle clock. Trends in Cell Biology, 1994, 4, 15-18.	3.6	135
107	Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell, 1994, 79, 487-496.	13.5	741
108	G1 phase progression: Cycling on cue. Cell, 1994, 79, 551-555.	13.5	2,668

#	ARTICLE	IF	CITATIONS
109	Editorial overview checks and balances. Current Opinion in Cell Biology, 1994, 6, 833-835.	2.6	10
110	Monoclonal Antibodies to Mammalian D-Type G1 Cyclins. Hybridoma, 1994, 13, 37-44.	0.9	28
111	Control of G1 Progression by Mammalian D-Type Cyclins. , 1994, , 17-23.		3
112	Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell, 1993, 73, 487-497.	13.5	1,056
113	Mammalian G1 cyclins. Cell, 1993, 73, 1059-1065.	13.5	1,994
114	Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell, 1992, 71, 323-334.	13.5	888
115	Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics, 1992, 13, 565-574.	1.3	246
116	Regulation of <i>CYL</i> /Cyclin D Genes by Colonyâ€Stimulating Factor 1. Novartis Foundation Symposium, 1992, 170, 209-219.	1.2	11
117	Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell, 1991, 65, 701-713.	13.5	1,179
118	Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling. Nature, 1991, 353, 361-363.	13.7	171
119	Regulation of mononuclear phagocyte proliferation by colony-stimulating factor-1. International Journal of Cell Cloning, 1990, 8, 46-62.	1.6	22
120	Functional Expression of the Human Receptor for Colony-Stimulating Factor 1 (CSF-1) in Hamster Fibroblasts: CSF-1 Stimulates Na+/H+exchange and DNA-Synthesis in the Absence of Phosphoinositide Breakdown. Growth Factors, 1990, 2, 289-300.	0.5	2
121	Signalâ€Response Coupling Mediated by the Transduced Colonyâ€Stimulating Factorâ€1 Receptor and its Oncogenic <i>fms</i> Variants in Naive Cells. Novartis Foundation Symposium, 1990, 148, 96-109.	1.2	0
122	The Mononuclear Phagocyte Colony-Stimulating Factor (CSF-1, M-CSF). Hematology/Oncology Clinics of North America, 1989, 3, 479-493.	0.9	31
123	The Macrophage Colony Stimulating Factor, CSF-1, and Its Receptor (c-fms). , 1989, , 193-207.		0
124	Colony-stimulating factor-1 receptor (c-fms). Journal of Cellular Biochemistry, 1988, 38, 179-187.	1.2	51
125	The fms oncogene. Biochimica Et Biophysica Acta: Reviews on Cancer, 1988, 948, 225-243.	3.3	27
126	Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes. Cell, 1988, 55, 655-661.	13.5	175

#	Article	IF	Citations
127	A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene) Tj ETQq1 1 0.784314 rgBT /Overlock	13.5	257
128	The colony-stimulating factor 1 (CSF-1) receptor (c-fms protooncogene product) and its ligand. Journal of Cell Science, 1988, 1988, 27-44.	1.2	30
129	Leukemia and lymphoma 1987. Cell, 1987, 48, 727-729.	13.5	4
130	Multilineage hematopoietic disorders induced by transplantation of bone marrow cells expressing the v-fms oncogene. Cell, 1987, 51, 663-673.	13.5	74
131	Transformation by the v-fms oncogene product: An analog of the CSF-1 receptor. Journal of Cellular Biochemistry, 1987, 33, 109-115.	1.2	6
132	Fibroblast and hematopoietic cell transformation by thefms oncogene (CSF-1 receptor). Journal of Cellular Physiology, 1987, 133, 83-87.	2.0	4
133	Transforming potential of the c-fms proto-oncogene (CSF-1 receptor). Nature, 1987, 325, 549-552.	13.7	370
134	Relationship of the c-fms Protooncogene Product to the CSF-1 Receptor. , 1987, , 81-91.		0
135	Antibodies to distal carboxyl terminal epitopes in the v-fms-coded glycoprotein do not cross-react with the c-fms gene product. Virology, 1986, 152, 432-445.	1.1	45
136	The v-fms oncogene induces factor independence and tumorigenicity in CSF-1 dependent macrophage cell line. Nature, 1986, 324, 377-380.	13.7	117
137	The c-fms Proto-Oncogene and the CSF-1 Receptor. , 1986, , 93-99.		4
138	Transmembrane orientation of glycoproteins encoded by the v-fms oncogene. Cell, 1985, 40, 971-981.	13.5	95
139	Expression of the human c-fms proto-oncogene in hematopoietic cells and its deletion in the 5qâˆ' syndrome. Cell, 1985, 42, 421-428.	13.5	181
140	The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF 1. Cell, 1985, 41, 665-676.	13.5	1,602
141	For the public record: Status of oncogene research. BioEssays, 1984, 1, 133-135.	1.2	0
142	Transformation by feline retroviruses. , 1984, 26, 45-58.		0
143	Mutant Feline Sarcoma Proviruses Containing the Viral Oncogene (v- <i>fes</i>) and Either Feline or Murine Control Elements. Journal of Virology, 1983, 45, 1004-1016.	1.5	37
144	Nucleotide sequences of feline retroviral oncogenes (v-fes) provide evidence for a family of tyrosine-specific protein kinase genes. Cell, 1982, 30, 775-785.	13.5	217

#	ARTICLE	IF	CITATIONS
145	Preparation of rat monoclonal antibodies to epitopes encoded by the viral oncogene (v-fms) of McDonough feline sarcoma virus. Journal of Cellular Biochemistry, 1982, 19, 275-280.	1.2	4
146	[35] Purification and assay of murine leukemia viruses. Methods in Enzymology, 1979, 58, 412-424.	0.4	11
147	Activation of endogenous type-C viral p30 antigen in chemically-induced rat hepatocellular carcinomas. International Journal of Cancer, 1978, 21, 756-761.	2.3	1
148	MAC-1, a new genetically transmitted type C virus of primates: â€œlow frequencyâ€•activation from stumptail monkey cell cultures. Cell, 1978, 13, 775-782.	13.5	77
149	A gene (Bevi) on human chromosome 6 is an integration site for baboon type C DNA provirus in human cells. Cell, 1978, 14, 995-1005.	13.5	57
150	Endogenous feline (RD-114) and baboon type C viruses have related specific RNA-binding proteins and genome binding sites. Virology, 1978, 84, 99-107.	1.1	9
151	Isolation and characterization of a new type D retrovirus from the Asian primate, Presbytis obscurus (spectacled langur). Virology, 1978, 84, 189-194.	1.1	88
152	Phosphorylation of murine type C viral p12 proteins regulates their extent of binding to the homologous viral RNA. Cell, 1977, 10, 487-496.	13.5	113
153	A new genetic locus, bevi, on human chromosome 6 which controls the replication of baboon type C virus in human cells. Cell, 1977, 12, 251-262.	13.5	40
154	A new class of murine retroviruses: Immunological and biochemical comparison of novel isolates from Mus cervicolor and Mus caroli. Virology, 1977, 80, 401-416.	1.1	45
155	Specific binding of the type C viral core protein p12 with purified viral RNA. Cell, 1976, 7, 21-32.	13.5	95
156	Baboons and their close relatives are unusual among primates in their ability to release nondefective endogenous type C viruses. Virology, 1976, 72, 278-282.	1.1	81
157	INTERSPECIES TRANSFER OF RNA TUMOR VIRUS GENES: IMPLICATIONS FOR THE SEARCH FOR â€œHUMANâ€•TYPE C VIRUSES. , 1976, , 369-384.		7
158	Infectious Primate Type C Virus Group: Evidence for an Origin from an Endogenous Virus of the Rodent, Mus caroli. Proceedings of the International Symposium on Comparative Leukemia Research, 1975, 43, 115-120.	0.1	1
159	Isolation of type-c viruses from the asian feral mousemus musculus molossinus. International Journal of Cancer, 1975, 15, 211-220.	2.3	50
160	Transplantable murine tumors release mouse-tropic and xenotropic type-c viruses. International Journal of Cancer, 1975, 15, 555-560.	2.3	14
161	Isolation of a type C virus (FS-1) from the European wildcat (Felis sylvestris). Virology, 1975, 66, 117-127.	1.1	15
162	Biologic and immunologic properties of porcine type C viruses. Virology, 1975, 66, 616-619.	1.1	90

#	ARTICLE	IF	CITATIONS
163	Infectious primate type C viruses: Three isolates belonging to a new subgroup from the brains of normal gibbons. Virology, 1975, 67, 335-343.	1.1	99
164	S-tropic murine type-C viruses: Frequency of isolation from continuous cell lines, leukemia virus preparations and normal spleens. International Journal of Cancer, 1974, 13, 587-598.	2.3	95
165	Infectious C-type virus isolated from a baboon placenta. Nature, 1974, 248, 17-20.	13.7	301
166	Endogenous baboon type C virus (M7): Biochemical and immunologic characterization. Virology, 1974, 58, 492-503.	1.1	76
167	Characterization of a type C virus released from the porcine cell line PK(15). Virology, 1974, 58, 65-74.	1.1	144
168	Radioimmunoassay of the major group specific protein of endogenous baboon type C viruses: Relation to the RD-114/CCC group and detection of antigen in normal baboon tissues. Virology, 1974, 61, 168-181.	1.1	85
169	Mixed splenocyte cultures and graft versus host reactions selectively induce an â€œS-tropicâ€•murine type C virus. Cell, 1974, 1, 55-58.	13.5	63
170	CELL SURFACE IMMUNOGLOBULIN. Journal of Experimental Medicine, 1972, 135, 1392-1405.	4.2	44
171	SYNTHESIS AND INTRACELLULAR TRANSPORT OF IMMUNOGLOBULIN IN SECRETORY AND NONSECRETORY CELLS *. Annals of the New York Academy of Sciences, 1971, 190, 250-267.	1.8	34
172	IMMUNOGLOBULIN SYNTHESIS AND SECRETION. Journal of Experimental Medicine, 1971, 133, 901-920.	4.2	47
173	Polymorphic control of subunit synthesis for the enzyme lactate dehydrogenase in the newt,Triturus viridescens. The Journal of Experimental Zoology, 1968, 169, 287-292.	1.4	6